YARW

SEC source: 0001209191-22-000858 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,879

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-22-000855 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,213

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-22-000852 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 760,633

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-067647 · doc4.xml · nonDerivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,500

F1 · kind: Shares were purchased pursuant to a 10b5-1 plan entered into by the reporting person on April 21, 2021.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.98 to $1.03, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-067649 · doc4.xml · nonDerivative · entry 1

Zeronda Tyler · CIK 0001867033 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,535

F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2021 and ending on November 30, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2021 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.

SEC source: 0001209191-21-067646 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 767,520

F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2021 and ending on November 30, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2021 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.

SEC source: 0001209191-21-058522 · doc4.xml · nonDerivative · entry 1

Zeronda Tyler · CIK 0001867033 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,348

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-058519 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,129

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-058516 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,697

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-058514 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 762,815

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-054837 · doc4.xml · derivative · entry 2

Zeronda Tyler · CIK 0001867033 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,860

Underlying: Common Stock · 60,860 shares

Expires 2031-09-02

F2 · derivative.exercise_date: 50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date.

SEC source: 0001209191-21-054837 · doc4.xml · nonDerivative · entry 1

Zeronda Tyler · CIK 0001867033 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,554

F1 · shares: Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date.

SEC source: 0001209191-21-054836 · doc4.xml · derivative · entry 2

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,860

Underlying: Common Stock · 60,860 shares

Expires 2031-09-02

F2 · derivative.exercise_date: 50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date.

SEC source: 0001209191-21-054836 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,609

F1 · shares: Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date.

SEC source: 0001209191-21-054834 · doc4.xml · derivative · entry 2

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,860

Underlying: Common Stock · 60,860 shares

Expires 2031-09-02

F2 · derivative.exercise_date: 50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date.

SEC source: 0001209191-21-054834 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,181

F1 · shares: Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date.

SEC source: 0001209191-21-054833 · doc4.xml · derivative · entry 2

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 320,313

Underlying: Common Stock · 320,313 shares

Expires 2031-09-02

F2 · derivative.exercise_date: 50% of the shares subject to the stock option award will vest on September 30, 2022, and the remaining 50% of the shares will vest thereafter in equal, quarterly installments, subject to the Reporting Person's continued service through the vesting date.

SEC source: 0001209191-21-054833 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 775,911

F1 · shares: Represents an award of restricted stock units, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. 100% of the awards will vest on September 30, 2023, subject to the Reporting Person's continued service through the vesting date.

SEC source: 0001209191-21-053498 · doc4.xml · nonDerivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.59 to $1.60, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001062993-21-007720 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 4,935,057

F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.

F2 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001062993-21-007667 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,185,057

F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $2.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.

F2 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001062993-21-007592 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,435,057

F1 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.06 to $2.59, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.

F1 · balance_after: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.06 to $2.59, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.

F2 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-21-047411 · doc4.xml · derivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2031-07-19

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022.

SEC source: 0001209191-21-047406 · doc4.xml · derivative · entry 1

Basta Steven L · CIK 0001417397 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2031-07-19

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022.

SEC source: 0001209191-21-047410 · doc4.xml · derivative · entry 1

Bruno Anthony D · CIK 0001374180 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2031-07-19

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022.

SEC source: 0001209191-21-047405 · doc4.xml · derivative · entry 1

BARBARI SHARON · CIK 0001240499 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2031-07-19

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022.

SEC source: 0001209191-21-047407 · doc4.xml · derivative · entry 1

Bright Rex · CIK 0001327501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2031-07-19

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022.

SEC source: 0001209191-21-047412 · doc4.xml · derivative · entry 1

Sandoval Elisabeth · CIK 0001632295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2031-07-19

F1 · derivative.exercise_date: These options vest over a 12 month period in equal, monthly installments, ending July 19, 2022.

SEC source: 0001209191-21-044983 · doc4.xml · nonDerivative · entry 1

Zeronda Tyler · CIK 0001867033 · Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,695

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-044980 · doc4.xml · nonDerivative · entry 1

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,246

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-044979 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,750

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-044977 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,322

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-044975 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 455,599

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-037193 · doc4.xml · nonDerivative · entry 1

Saik Andrew · CIK 0001616284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,468

F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2020 and ending on May 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on May 28, 2021 (the last trading day of the offering period).

SEC source: 0001209191-21-037189 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 474,458

F1 · shares: These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2020 and ending on May 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on May 28, 2021 (the last trading day of the offering period).

SEC source: 0001209191-21-036302 · doc4.xml · nonDerivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,500

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.48 to $3.6950, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001062993-21-004265 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,773,954

F1 · shares: The share numbers reported on this Form 4 give effect to the Issuer's one-for-four reverse stock split effected on February 10, 2021 (the "Reverse Stock Split").

F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $4.20, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.

F3 · price: The reported price gives effect to the Reverse Stock Split. Without giving effect to the Reverse Stock Split, the weighted average price reported would be $0.92 per share, at prices ranging from $0.875 to $1.05 per share, inclusive.

F1 · balance_after: The share numbers reported on this Form 4 give effect to the Issuer's one-for-four reverse stock split effected on February 10, 2021 (the "Reverse Stock Split").

F4 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0001209191-21-024412 · doc4.xml · nonDerivative · entry 1

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,397

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-024411 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,833

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-024410 · doc4.xml · nonDerivative · entry 1

Saik Andrew · CIK 0001616284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,451

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-024408 · doc4.xml · nonDerivative · entry 1

Domzalski David · CIK 0001727794 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 473,517

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-024409 · doc4.xml · nonDerivative · entry 1

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,873

F1 · shares: Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

SEC source: 0001209191-21-020834 · doc4.xml · nonDerivative · entry 1

LEPORE PATRICK G · CIK 0001055404 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.39 to $7.42, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-013821 · doc4.xml · derivative · entry 2

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,575

Underlying: Common Stock · 64,575 shares

Expires 2031-02-22

F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

SEC source: 0001209191-21-013821 · doc4.xml · nonDerivative · entry 1

Wiley Matthew T. · CIK 0001759703 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,970

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

SEC source: 0001209191-21-013818 · doc4.xml · derivative · entry 2

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,162

Underlying: Common Stock · 68,162 shares

Expires 2031-02-22

F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

SEC source: 0001209191-21-013818 · doc4.xml · nonDerivative · entry 1

Stuart Iain · CIK 0001727756 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,778

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

SEC source: 0001209191-21-013814 · doc4.xml · derivative · entry 2

Saik Andrew · CIK 0001616284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,162

Underlying: Common Stock · 68,162 shares

Expires 2031-02-22

F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

SEC source: 0001209191-21-013814 · doc4.xml · nonDerivative · entry 1

Saik Andrew · CIK 0001616284 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,213

F1 · shares: Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc.

F2 · shares: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.

SEC source: 0001209191-21-013813 · doc4.xml · derivative · entry 2

Harsch Mutya · CIK 0001727809 · Chief Legal Officer and GC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,162

Underlying: Common Stock · 68,162 shares

Expires 2031-02-22

F2 · derivative.exercise_date: The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025.